Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The company has a strong pipeline of drugs targeting DR3, a novel and difficult-to-target protein involved in inflammatory and immune-mediated diseases. The company's lead asset, SL-325, has the potential to be a first-in-class DR3 antagonist antibody and has shown promising results in preclinical studies. The company also has a second clinical asset, the DR3 x IL-23R bispecific SL-846, which further adds to its pipeline optionality. The company's potential for success is supported by its differentiated approach and its experienced management team. However, as with any biotech company, there are inherent risks such as clinical and regulatory failure, competition from other drugs, and manufacturing challenges that could impact its financial performance. Overall, we believe Shattuck Labs' current market value does not fully reflect the potential value of its platform technology and lead asset, and we see significant upside potential for the stock in the near term.

Bears say

Shattuck Labs is a biotechnology company that focuses on developing treatments for inflammatory and autoimmune diseases. While the company has a promising lead asset, SL-325, clinical trial results for this drug have not met expectations. Additionally, the company's financials show a lack of revenue and a limited cash runway, potentially indicating a lack of resources to support future development.

Shattuck Labs (STTK) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 7 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.